The Conversation (0)
BIOLASE, Inc. (NASDAQ:BIOL) received formal notice from the first instance Düsseldorf District Court that BIOLASE has won its patent infringement case, where Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470.
BIOLASE, Inc. (NASDAQ:BIOL) received formal notice from the first instance Düsseldorf District Court that BIOLASE has won its patent infringement case, where Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470.
As quoted in the press release:
In the ruling, the Düsseldorf Court found that Fotona’s Fidelis dental laser system infringes on BIOLASE’s European Patent EP 1 560 470. BIOLASE’s European Patent EP 1 560 470 has broad claims relating to the output of optical energy of lasers; specifically, the conditions of laser-induced cutting of biological tissue where air-water spray is applied to the tissue for stimulation of mechanical cutting. The Düsseldorf Court accepted BIOLASE’s requests for injunctive relief, product recall, rendering of account, and cash damages.
Click here to read the BIOLASE (NASDAQ:BIOL) press release
BIOLASE, Inc. Chairman and CEO, Federico Pignatelli, said:
This is a great victory for BIOLASE and our extensive portfolio of international patents. The Düsseldorf Court awarded BIOLASE full damages, which we estimate could amount to several million Euros for the German market alone, and injunctive relief in the critical German market which is fundamental to our European sales strategy.
